IP Library Granted Patent US 12,558,470
Granted Patent B2
US 12,558,470 · App. 18/259,980 · Granted Feb 24, 2026

Guided blood filtration therapy, systems, and methods

Inventor: David Lerner (St. Paul, MN)
Assignee: CorRen Medical, Inc.
A61M1/3403G16H20/40A61M2202/0413A61M2205/3303A61M2205/502A61M2230/005A61M2230/04A61M2230/207A61M2230/42A61M2230/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,558,470
App. No.
18/259,980
Granted
Feb 24, 2026
Kind
B2
Abstract

A blood filtration system may include one or more sensors. The sensors may determine physiological parameters, for instance one or more of venous oxygen saturation (Sv02) or hematocrit of a patient. The blood filtration system may include a controller. The controller may communicate with the one or more sensors. The controller may monitor the physiological parameters using the sensors. The controller may include a display module that generates content. A display may present the content. The content may include a diagnostic matrix having a diagnostic point. The display module may change the diagnostic point within the diagnostic matrix according to changes in the monitored physiological parameters.

Claims (40)

1 . A blood filtration system, comprising:

one or more sensors configured to determine one or more physiological parameters including venous oxygen saturation (SvO2) and hematocrit of a patient;

a controller in communication with the one or more sensors, wherein:

the controller is configured to monitor the physiological parameters using the sensors;

the controller includes a display module configured to generate content including a diagnostic matrix having a diagnostic point, and the display module is configured to change the diagnostic point within the diagnostic matrix according to changes in the monitored physiological parameters; and

the controller includes a therapy guidance module configured to determine a suggested corrective action based on the monitored physiological parameters, and the suggested corrective action is included in the content; and

a display configured for presenting the content.

2 . The blood filtration system of claim 1 , wherein:

the display module is configured to determine a zone of stability associated with the monitored physiological parameters; and

the zone of stability includes one or more value ranges for the physiological parameters.

3 . The blood filtration system of claim 2 , wherein the display is configured to present the diagnostic matrix and the zone of stability.

4 . The blood filtration system of claim 1 , wherein the display is configured to present the suggested corrective action, the diagnostic point, and a zone of stability.

5 . The blood filtration system of claim 1 , wherein the suggested corrective action includes changes in an extraction rate of filtrate fluid from blood of a patient.

6 . The blood filtration system of claim 5 , wherein the display is configured to display the suggested corrective action and the diagnostic matrix.

7 . The blood filtration system of claim 1 , wherein:

the therapy guidance module is configured to compare the monitored hematocrit with a hematocrit value range, the hematocrit value range extending between a first hematocrit value and a second hematocrit value;

the controller is configured to provide the suggested corrective action based on the comparison of the monitored hematocrit with the hematocrit value range.

8 . The blood filtration system of claim 7 , wherein:

the controller includes a comparator configured to compare the monitored SvO2 with a SvO2 value range, the SvO2 value range extending between a first SvO2 value and a second SvO2 value;

the controller is configured to provide the suggested corrective action based on the comparison of the monitored SvO2 with the SvO2 value range.

9 . The blood filtration system of claim 8 , wherein the suggested correction includes increasing a filtration rate when the hematocrit is within the hematocrit value range and the SvO2 is within the SvO2 value range.

10 . The blood filtration system of claim 8 , wherein the suggested correction includes decreasing a filtration rate when the hematocrit is outside the hematocrit value range and the SvO2 is within the SvO2 value range.

11 . The blood filtration system of claim 8 , wherein the suggested correction includes setting a filtration rate to zero when the hematocrit is outside the hematocrit value range and the SvO2 is outside the SvO2 value range.

12 . The blood filtration system of claim 11 , wherein the controller is configured to wait for a specified time period before providing the suggested correction.

13 . The blood filtration system of claim 8 , wherein the controller is configured to set a filtration rate to zero when the hematocrit is outside the hematocrit value range and the SvO2 is outside the SvO2 value range.

14 . The blood filtration system of claim 8 , wherein the controller is configured to set a filtration rate to zero when the hematocrit is outside the hematocrit value range and the SvO2 is outside the SvO2 value range.

15 . The blood filtration system of claim 1 , wherein the physiological parameters include one or more of relative blood volume, absolute blood volume, plasma volume, oxygen extraction ratio, ejection time, stroke volume, carotid flow time, cardiac output, cardiac power, central venous pressure, mean arterial pressure, systemic vascular resistance, heart rate, respiratory rate, cardiac power, hemoglobin concentration, extracellular fluid volume, or thoracic fluid content.

16 . The blood filtration system of claim 15 , wherein the controller includes an evaluation module configured to determine the physiological parameters using the one or more sensors.

17 . The blood filtration system of claim 10 , wherein the display module is configured to change a size of the diagnostic point in correspondence with changes in one or more of the monitored parameters.

18 . The blood filtration system of claim 17 , wherein the display module is configured to change a color of the diagnostic point in correspondence with changes in one or more of the monitored parameters.

19 . The blood filtration system of claim 1 , wherein the display module is configured to move the diagnostic point along one or more axis, the one or more axis corresponding with values of the monitored diagnostic parameters.

20 . The blood filtration system of claim 1 , wherein the physiological parameters comprise hemodynamic parameters that affect hemodynamic stability of the patient.

21 . The blood filtration system of claim 1 , wherein the controller is configured to determine a systemic vascular resistance (SVR) of the patient using the monitored physiological parameters.

22 . The blood filtration system of claim 21 , wherein:

the controller determines a first figure of merit corresponding to first basis of change in the SVR; and

the controller determines a second figure of merit corresponding to a second basis of change in the SVR.

23 . The blood filtration system of claim 21 , wherein:

the SVR equals a first quantity divided by a second quantity;

the first quantity equals a difference between a mean arterial pressure of a patient and a central venous pressure of the patient;

the second quantity equals a cardiac output of the patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2026
From: CORREN MEDICAL, INC.
To: ACQUMEN MEDICAL, INC.
Reel/Frame 073926/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2024
From: NUWELLIS, INC.
To: CORREN MEDICAL, INC.
Reel/Frame 067704/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2023
From: LERNER, DAVID
To: NUWELLIS, INC.
Reel/Frame 064737/0711 →
Continuity (2)
Provisional Application 63199485 · Dec 31, 2020
Related Publication 20240066199A1 · Feb 29, 2024
References Cited (20)
US 5178154A · Ackmann et al. · 1993 [cited by applicant]
US 5511553A · Segalowitz · 1996 [cited by applicant]
US 5928180A · Krivitski · 1999 [cited by examiner]
US 6610024B1 · Benatti · 2003 [cited by examiner]
US 7788038B2 · Oshita · 2010 [cited by examiner]
US 8000779B2 · Bartnik et al. · 2011 [cited by applicant]
US 8473041B2 · Bartnik · 2013 [cited by examiner]
US 20140118166A1 · Hampapuram · 2014 [cited by examiner]
CN 209826715U · 2019 [cited by applicant]
DE 102017130548A1 · 2019 [cited by applicant]
JP 2012254251A · 2012 [cited by examiner]
KR 20120120262A · 2012 [cited by applicant]
WO WO2008029396A2 · 2008 [cited by applicant]
WO WO2017139839A1 · 2017 [cited by applicant]
WO WO2018202661A1 · 2018 [cited by applicant]
WO WO2020061619A1 · 2020 [cited by applicant]
WO WO2022147482A1 · 2022 [cited by applicant]
“International Application Serial No. PCT/US2021/073205, International Search Report mailed Jun. 3, 2022”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2021/073205, Invitation to Pay Additional Fees mailed Mar. 14, 2022”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2021/073205, Written Opinion mailed Jun. 3, 2022”, 9 pgs. [cited by applicant]